Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
about
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune DiseasesPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerPotential role of High mobility group box 1 in hepatocellular carcinomaPredictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasisCo-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.HMGB1 in health and disease.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese populationInfliximab enhances the therapeutic effects of 5-fluorouracil resulting in tumor regression in colon cancer.Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.The role of high mobility group box 1 (HMGB1) in colorectal cancer.TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer.Personalized medicine approaches in epilepsy.Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysisA comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease.C-reactive protein and high mobility group box 1 in dogs with gastric dilatation and volvulus.Clinical and prognostic significance of high-mobility group box-1 in human gliomas.The immune response to secondary necrotic cells.S100A9 gene silencing inhibits the release of pro-inflammatory cytokines by blocking the IL-17 signalling pathway in mice with acute pancreatitis.Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.Trial Watch: Chemotherapy with immunogenic cell death inducers.
P2860
Q26768480-09E097FF-4CE8-4030-89F7-62F57E039EB9Q26795466-1895BA6B-9C1D-4303-9A87-DB39DA15D524Q26864508-9261DC07-7BB0-46B5-BFA6-29D4CDD63ADDQ33914190-97C532DB-D795-4062-88CD-EA77CD62F778Q33932673-44703908-7539-47DB-A598-BB28790B5349Q34428389-928F6B5E-2239-4640-BBF3-B1F882AE2C71Q34502899-DDADD6DA-65E7-46F2-B2A8-1A5CB4436E5BQ34622835-A5F45C91-6548-49ED-BD3B-C1C97DE9151FQ35506253-9BB9C17B-B405-4C8A-94A5-504D90AE47EAQ36985164-65B35F1E-6CD5-4CFB-AD32-4E0152D8F81EQ37251612-1DE54B9B-C6D3-44A3-B828-3691BB9186EAQ37320785-678F3BAD-3620-41BB-B645-6F6D9F005E43Q37321088-CA2EEA74-D663-4AC3-B866-DD6FAA6DD542Q37685447-5B4B3D2F-B0F0-48F5-84FD-50442F12F194Q37729984-8551C304-2117-4729-95A7-0A9688AC9C63Q38116712-CFE56A10-9B37-4CBD-B1BD-5230A00B50E1Q38262011-E78E7787-C1B8-4A44-A400-A87030E436B7Q38790788-030A7D7A-6E5E-4B47-9106-0B94417FBAA0Q39281286-491C1FD4-33BA-43E9-980A-81388F0B5313Q40431064-369E9C71-95AC-4300-BAED-A76896EF8B8CQ41953972-B3D20E25-D524-4FA7-A3D8-D9D25FC7B2CFQ41983273-32BFF99A-DB73-4611-A02E-A979BF5D0799Q42371859-48EC7A1C-FBFF-4D69-9379-5A9FF01B70E3Q50019761-301F8479-D911-4F65-91D8-EFBAD095D887Q50943644-28F1D9D0-EA7A-4ACB-9238-838D8A4B44B0Q55260834-AD6FF60C-6897-4D30-850D-013D5E9F6A14
P2860
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Immunogenic cell death biomark ...... in colorectal cancer patients.
@en
Immunogenic cell death biomark ...... in colorectal cancer patients.
@nl
type
label
Immunogenic cell death biomark ...... in colorectal cancer patients.
@en
Immunogenic cell death biomark ...... in colorectal cancer patients.
@nl
prefLabel
Immunogenic cell death biomark ...... in colorectal cancer patients.
@en
Immunogenic cell death biomark ...... in colorectal cancer patients.
@nl
P2093
P2860
P356
P1476
Immunogenic cell death biomark ...... in colorectal cancer patients.
@en
P2093
Dorothea Nagel
Klaus Tatsch
Petra Stieber
Ralf-Thorsten Hoffmann
Stefan Holdenrieder
Tobias Jakobs
Yvonne Nadine Fahmueller
P2860
P304
P356
10.1002/IJC.27894
P577
2013-01-18T00:00:00Z